Business & Regulation

Job cuts at the FDA spark concern, with Robert Califf saying the agency as we know it is “finished.”

Looking ahead to the next 5–10 years, what will be the key disruptors and/or what can be improved upon in the pharma industry?

We ask James Chambers from Tufts Medical Center about the challenges faced by biosimilars in the US.

We dive into the archive of 2021 for insight and inspiration – this time with Peter Marks

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track

Rumours claim that a well-known vaccine skeptic has been appointed to lead study on links between vaccines and autism.

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr.

An industry survey looks at changing attitudes and challenges in digital innovation for clinical research. Uptake is slow but steady.

Thoughts on the US National Institutes of Health and its role in funding research for non-opioid therapeutics.

FDA letter sent to Edenbridge Pharmaceuticals demonstrates the challenges of getting pharma advertising right.